Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.42 |
| ▸ | CDC25B | P30305 | 6/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712002 | 0.90 | NT5E (0.48) | NT5ETACR2PTPN1CDC25BPTPN2 | |
| SCHEMBL8723296 | 0.87 | NT5E (0.53) | NT5ETACR2SSTR4PTPN1CDC25B | |
| SCHEMBL7353598 | 0.82 | TSHR (0.45) | NT5ETACR2 | |
| SCHEMBL7353615 | 0.82 | TSHR (0.45) | NT5ETACR2 | |
| SCHEMBL7353601 | 0.82 | TSHR (0.45) | NT5ETACR2 | |
| SCHEMBL7353619 | 0.82 | TSHR (0.45) | NT5ETACR2 | |
| SCHEMBL20870545 | 0.82 | HTR1A (0.43) | NT5ETACR2SSTR4PTPN1CDC25B | |
| SCHEMBL19736552 | 0.82 | HTR1A (0.43) | NT5ETACR2SSTR4PTPN1CDC25B | |
| SCHEMBL14278490 | 0.82 | HTR1A (0.43) | NT5ETACR2SSTR4PTPN1CDC25B | |
| SCHEMBL22288949 | 0.78 | TACR2 (0.52) | NT5ETACR2SSTR4PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762397-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11945834-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-111801341-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3762397-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019173587-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945834-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, NTPCR | NT5E 83/4885TACR2 4721/4885SSTR4 4767/4885 |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, NTPCR | NT5E 83/4885TACR2 4721/4885SSTR4 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.